In particular, crizotinib, an ATP-competitive, small-molecule multi-targeted TKI, exerts in vivo anti-tumor activity and in vitro activity against the kinase domains of RTKs, specifically, ALK (anaplastic lymphoma kinase), MET (hepatocyte growth factor receptor), and ROS1 (proto-oncogene receptor tyrosine kinase 1)9. This evidence concerns the gene MET and neoplasm.